They are the first 6 out of 120 volunteers, between the ages of 18-59 years old, who will receive 2 shots of the vaccine or a placebo, with each shot spaced 28 days apart.
The vaccine has been researched and developed by the Institute of Vaccines and Medical Biologicals or (IVAC). The animal testing phase was completed in late January. Preclinical study results of Covivac in India, the U.S., and Vietnam showed that the vaccine is effective against the UK and South Africa strains of nCoV.
